Bristol-Myers Squibb’s much-criticized chief executive is now out of the picture, but company earnings prospects remain bleak and the absence of a permanent new leader could make the drugmaker prey to a takeover, analysts said on Tuesday.
*For more on this story,
read the full Reuters article.
